.Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AH04_Quetiapine.Quetiapine

Information

Quetiapine is an atypical antipsychotic medication approved for the treatment of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder. It acts mainly by antagonism of serotonin (5-HT2A) and dopamine (D2) receptors. Quetiapine is widely prescribed and remains in routine clinical use today.

Pharmacokinetics

Pharmacokinetic parameters from healthy adult volunteers after single-dose oral administration.

References

1. Fukushi, R, et al., & Takada, A (2020). Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression. Clinical therapeutics 42(6) 1067–1076.e2. DOI:10.1016/j.clinthera.2020.04.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32518042

2. Lin, M, et al., & Zhao, Q (2024). The impact of CYP3A5*3 on oral quetiapine: A population pharmacokinetic model in Chinese bipolar disorder patients. Journal of affective disorders 351 309–313. DOI:10.1016/j.jad.2024.01.170 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38262522

3. Li, Q, et al., & Si, TM (2014). Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. Clinical pharmacokinetics 53(5) 455–465. DOI:10.1007/s40262-013-0127-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24385309

Revisions

• 06/2025 initial generated model